Pharmacokinetic Study in Cerebral Spinal Fluid After a Single Dose of AVI-4020
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00387283|
Recruitment Status : Completed
First Posted : October 13, 2006
Last Update Posted : July 8, 2009
During a clinical study of people with severe West Nile virus infections, it was determined that the drug AVI-4020 crossed the blood-brain barrier. This study will assess the amount of drug that goes across the blood-brain barrier and the drug levels measured in both the blood and urine.
The objective of this study is to find out how much and how fast this drug crosses this barrier.
|Condition or disease||Intervention/treatment||Phase|
|West Nile Virus||Drug: AVI-4020 Injection||Phase 1|
AVI-4020 was designed to interfere with West Nile virus translation, and has been shown to cross the blood-brain barrier in both normal and inflamed meninges in a clinical study in patients with severe West Nile virus disease.
At issue, is whether this observation is limited to AVI-4020 PMO drug, or is observed with other PMO drugs. This study is one of three to assess the specific ability of PMO drugs to cross the blood-brain barrier, using similar dosing, and PK assessment time points. In order to rigorously assess the pharmacokinetics, this study is being performed in healthy volunteers at a single point in time.
The ability of other PMO drugs to cross the blood-brain barrier will set the stage for future studies that exploit this product characteristic.
|Study Type :||Interventional (Clinical Trial)|
|Enrollment :||14 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Pharmacokinetic Study of AVI-4020 in Cerebral Spinal Fluid Among Healthy Adult Males Following Intravenous Administration|
|Study Start Date :||October 2006|
|Actual Primary Completion Date :||December 2006|
|Actual Study Completion Date :||June 2009|
- To determine if the study drug penetrates the blood brain barrier following a single dose of AVI-4020, and if it does, the associated CSF, plasma and urine pharmacokinetics
- Safety, Tolerability
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00387283
|United States, Washington|
|Tacoma, Washington, United States, 98418|
|Principal Investigator:||Paula M Shaw, M.D.||NW Kinetics|